ContraFect names Steven Gilman as Chief Executive Officer

The US firm is a developer of protein and anti-body therapeutics

ContraFect, a Yonkers, NY, US-based biotechnology company, has named Steven Gilman as Chief Executive Officer, effective immediately. Dr Gilman has been Interim Chief Executive since 21 March 2016. He will continue as Chairman of the Board of Directors of the company, which is focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases.

'The Board is pleased to have an executive with the experience and credentials of Steve Gilman to serve as Chief Executive Officer at ContraFect,' said Sol Barer, ContraFect's Lead Independent Director. 'Steve is a proven leader in the infectious disease field, and has extensive experience in the development and commercialisation of new anti-infective agents.'

You may also like